CLINICAL TRIALS PROFILE FOR ADSTILADRIN

All Clinical Trials for ADSTILADRIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06390111 ↗	A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.	WITHDRAWN	Ferring Pharmaceuticals	PHASE4	2024-06-17	In this phase 4 trial (000439), subjects with NMIBC CIS (± high-grade Ta/T1) who have not responded to their first dose of nadofaragene firadenovec (commercial ADSTILADRIN received before trial entry) will be offered reinduction when entering the trial.

Clinical Trial Conditions for ADSTILADRIN

Condition Name

Condition Name for ADSTILADRIN
Intervention	Trials
Bladder Cancer	1
CIS	1
Ta/T1	1

Condition MeSH

Condition MeSH for ADSTILADRIN
Intervention	Trials
Urinary Bladder Neoplasms	1

Clinical Trial Locations for ADSTILADRIN

Trials by Country

Trials by Country for ADSTILADRIN
Location	Trials
United States	2

Trials by US State

Trials by US State for ADSTILADRIN
Location	Trials
Georgia	1
Arkansas	1

Clinical Trial Progress for ADSTILADRIN

Clinical Trial Phase

Clinical Trial Phase for ADSTILADRIN
Clinical Trial Phase	Trials
PHASE4	1

Clinical Trial Status

Clinical Trial Status for ADSTILADRIN
Clinical Trial Phase	Trials
WITHDRAWN	1

Clinical Trial Sponsors for ADSTILADRIN

Sponsor Name

Sponsor Name for ADSTILADRIN
Sponsor	Trials
Ferring Pharmaceuticals	1

Sponsor Type

Sponsor Type for ADSTILADRIN
Sponsor	Trials
INDUSTRY	1

ADSTILADRIN clinical trials update, market analysis and projection (adalteparin/gene therapy delivery asset) Adstiladrin (nadofaragene firadenovec; gene therapy) is in late-stage clinical development with regulatory progress tied to the FDA review of intravesical gene delivery. Public clinical and commercial disclosure supports a near-to-mid-term urology market entry case centered on NMIBC populations, with competitive pressure from intravesical BCG and newer agents (chemotherapy, immunotherapy, and device approaches). Market sizing and forecasts depend on durability, retreatment acceptance, payer coverage, and sequencing versus BCG and second-line options.

What is Adstiladrin (nadofaragene firadenovec) and what’s its clinical development status?

Adstiladrin is a gene therapy administered intravesically for non-muscle invasive bladder cancer (NMIBC). The product is designed to deliver a gene encoding interferon-based biology to the bladder urothelium, with intended treatment durability relative to standard intravesical regimens.

Which FDA pathway and label concept has driven development

• Adstiladrin’s development is structured around NMIBC endpoints used for regulatory decisions in bladder cancer, including high-risk and recurrent disease cohorts.
• Intravesical delivery and retreatment patterns are central to trial interpretation because they shape real-world dosing intensity.

What clinical results anchor the regulatory value proposition

Across late-stage data readouts, the market case has depended on:

• Rates of complete response (CR) or high-grade recurrence-free outcomes after induction.
• Durability of response over time (lower retreatment frequency compared with conventional intravesical schedules is the commercial lever).
• Tumor category positioning, especially in BCG-unresponsive or BCG-inadequate populations.

Latest status (trial programs and readouts): Public disclosures for Adstiladrin have focused on long-term follow-up from pivotal/confirmatory studies and update presentations at major oncology meetings, with emphasis on durability and retreatment outcomes in NMIBC.

Which clinical trials have reported data for Adstiladrin, and what are the key endpoint updates?

The Adstiladrin clinical story is best understood via a small set of late-stage NMIBC trials that generate CR and response durability signals.

Pivotal trial structure and endpoint emphasis

Late-stage studies have typically used:

• Response assessments after induction dosing.
• Time-to-recurrence or durability windows.
• Safety reporting emphasizing local urinary events and systemic tolerability for intravesical gene therapy.

How to interpret endpoint movement for commercial projections

For payer and provider uptake, the most market-relevant elements are:

• Proportion achieving durable response after a limited induction course.
• Retreatment rate thresholds that keep lifetime treatment cost manageable.
• Durability in subgroups aligned to real-world treatment sequences (BCG-unresponsive, high-risk CIS, papillary tumors).

When could Adstiladrin lose exclusivity, and how does that affect revenue projections?

Exclusivity timing for Adstiladrin is dictated by a combination of:

• Patent term (composition of matter, delivery constructs, and method-of-use claims).
• Regulatory exclusivities (for biologics/gene therapies when applicable).
• Any market exclusivity tied to initial approval timing.

Exclusivity-to-forecast mapping: Business planning typically assumes the first commercial peak occurs in the first several years post-launch, with a second phase dependent on expansion into broader risk strata and conversion to earlier-line use.

What patents protect Adstiladrin, and how strong is the patent estate for NMIBC intravesical use?

An IP posture for Adstiladrin depends on whether the estate is anchored in:

• The gene construct and vector system.
• Intravesical administration methods and dosing schedules.
• Method-of-use claims tied to NMIBC risk categories and response assessment endpoints.

Commercial implication: Patent strength impacts launch protection duration and affects licensing leverage for adjacent indications or formulation/dosing modifications.

What generic entry risks exist for Adstiladrin? Is an interchangeable product feasible?

Adstiladrin is a gene therapy delivered intravesically. The pathway to “generic” is not analogous to small-molecule generics:

• Substitution would require an equivalent product under biologics/gene therapy frameworks.
• Legal and regulatory pathways are typically more complex than Paragraph IV for standard oral drugs.
• Competitive entry is more likely via biosimilar-like pathways or alternative gene therapies or intravesical standards rather than true generics.

Projection effect: The main competitive threat to Adstiladrin revenue typically comes from:

• Uptake into segments where competing therapies already have installed base.
• Faster durability demonstrations from entrants.
• Payer restrictions around cost-effectiveness compared with established intravesical options.

What is the Orange Book status of Adstiladrin, and what does that mean for competition?

Gene therapies are generally not listed in the FDA Orange Book in the same way as small-molecule drugs. Competitive entry planning should treat it as a biologics-like regulatory category unless FDA listings indicate otherwise for specific approval components.

Market implication: Lack of Orange Book “generic” mechanics shifts the competitive landscape to:

• Biologics/gene-therapy development timelines.
• IP challenges focused on gene constructs and methods of use rather than simple label carve-outs.

How does Adstiladrin compare with BCG, intravesical chemotherapy, and newer NMIBC therapies?

Adstiladrin’s competitive position hinges on whether it can:

• Reduce recurrence in high-risk NMIBC.
• Delay or avoid cystectomy compared with alternatives.
• Deliver durable responses with fewer treatment cycles.

Key comparison dimensions for market share

• Durability of response: time to recurrence and durable CR proportions.
• Treatment burden: induction schedules, retreatment frequency, clinic resource intensity.
• Safety and tolerability: local urinary symptoms, systemic AEs.
• Sequencing: position after BCG failure versus earlier-line use.

Where adoption is likely to be fastest

• Settings with established urology oncology pathways treating CIS/high-risk recurrent NMIBC.
• Centers with experience delivering intravesical therapies and tracking response endpoints.

What clinical adoption barriers could limit Adstiladrin uptake?

Commercial uptake depends on more than efficacy:

• Retreatment and protocol adherence requirements.
• Clinician confidence in long-term durability.
• Patient selection rules tied to trial endpoints.
• Reimbursement and budget impact in community settings.

Forecast sensitivity: Uptake rate is highly sensitive to payer coverage policies and the degree to which the therapy becomes positioned as a preferred option in BCG-unresponsive or second-line segments.

Market analysis: How big is the NMIBC opportunity for Adstiladrin, and what drives penetration?

The NMIBC market is defined by:

• Prevalent and incident high-risk and recurrent populations (including CIS and high-grade disease after prior intravesical therapy).
• Treatment lines: first-line BCG, BCG-unresponsive management, and subsequent lines including alternative intravesicals and systemic options.

Demand drivers

• Rising identification of high-grade NMIBC and CIS.
• Provider preference for therapies that reduce procedural burden or improve response durability.
• Competitive displacement when a therapy shows strong durability or retreatment advantages.

Adoption drivers

• Evidence of durable response translates into stronger retention at leading urology centers.
• Institutional formularies and payer policies determine whether the product becomes standard-of-care versus fallback use.

Revenue projection: What is the base case peak-year for Adstiladrin and what scenarios matter?

A defensible projection requires mapping:

1. Launch timing and ramp rate
2. Treated patient volumes by risk segment
3. Average number of administrations per treated patient
4. Net price after discounts, rebates, and payer negotiations
5. Retreatment and discontinuation assumptions

Base-case framing for planning: Forecasts typically model a ramp over several years, with peak driven by:

• Expansion from narrow trial-aligned segments into broader high-risk NMIBC categories.
• Evidence durability that supports guideline adoption and payer acceptance.
• Competitor performance and sequencing choices.

Scenario levers:

Last updated: May 14, 2026

• Durability duration: longer durability supports higher lifetime treated volume retention.
• Payer policy: restrictive coverage reduces conversion from eligible to treated.
• Competitive entrants: new intravesical agents with comparable or better durability reduce incremental share.

What ongoing trials or follow-up studies could change Adstiladrin’s commercial outlook?

Follow-up updates can shift:

• Confidence in long-term durability and retreatment patterns.
• Subgroup signals tied to CIS versus papillary disease.
• Safety profiles that affect clinic acceptance.

Market impact mechanism: Strong long-term confirmation supports payer negotiations, guideline inclusion, and broader eligible patient pools.

What competitor landscape threatens Adstiladrin’s projected share in NMIBC?

Threats generally come from:

• New intravesical immunotherapies and chemotherapies with recurrence reduction.
• Device-assisted or multimodal approaches used in high-risk NMIBC.
• Systemic therapies entering later lines if response durability is inadequate.

How competitors win

• Faster cycle times and simplified administration.
• Strong real-world tolerability.
• Payer-preferred pricing and inclusion in treatment algorithms.

Key Takeaways

• Adstiladrin’s market case depends on durable responses in NMIBC and on clinic/payer acceptance of its intravesical gene delivery schedule.
• Forecasts are most sensitive to durability, retreatment rate, and payer coverage decisions rather than early CR rate alone.
• Competitive risk is higher from next-generation intravesical products than from “generic” entry, given gene therapy regulatory and IP realities.
• Any long-term follow-up that confirms durability and improves subgroup performance is the principal catalyst for revenue ramp and sustained demand.

FAQs

1. What NMIBC subpopulations are most likely to drive Adstiladrin uptake?
2. How do retreatment frequency assumptions change Adstiladrin revenue forecasts?
3. What are the main safety considerations for intravesical gene therapy adoption in community urology practice?
4. How do payers evaluate cost-effectiveness for durable intravesical responses versus BCG and chemotherapy?
5. What trial follow-up endpoints are most likely to shift guideline positioning for Adstiladrin?

References

1. FDA. Drug therapy approvals and related regulatory information for nadofaragene firadenovec (Adstiladrin).
2. ClinicalTrials.gov. Nadofaragene firadenovec (Adstiladrin) study listings and status updates.
3. Peer-reviewed publications and conference proceedings reporting efficacy and safety for nadofaragene firadenovec in NMIBC.
4. NCCN Bladder Cancer guideline updates covering NMIBC and BCG-unresponsive treatment options.